Search results for "Cholesterol"

showing 10 items of 1211 documents

Myristic acid is associated to low plasma HDL cholesterol levels in a Mediterranean population and increases HDL catabolism by enhancing HDL particle…

2016

Background: HDL-C plasma levels are modulated by dietary fatty acid (FA), but studies investigating dietary supplementation in FA gave contrasting results. Saturated FA increased HDL-C levels only in some studies. Mono-unsaturated FA exerted a slight effect while poly-unsaturated FA mostly increased plasma HDL-C. Aims: This study presents two aims: i) to investigate the relationship between HDL-C levels and plasma FA composition in a Sicilian population following a "Mediterranean diet", ii) to investigate if FA that resulted correlated with plasma HDL-C levels in the population study and/or very abundant in the plasma were able to affect HDL catabolism in an "in vitro" model of cultured hep…

Male0301 basic medicineSettore MED/09 - Medicina InternaMediterranean dietCellHepG2 cellMyristic acid030204 cardiovascular system & hematologyDiet MediterraneanMyristic AcidSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineSicilyeducation.field_of_studyLiver NeoplasmsHep G2 CellsMiddle Agedmedicine.anatomical_structurePopulation studyFemalelipids (amino acids peptides and proteins)Composition (visual arts)Cholesterol EstersCardiology and Cardiovascular MedicinePopulation studyProtein BindingAdultmedicine.medical_specialtyCarcinoma HepatocellularPopulationHDL cholesterol level03 medical and health sciencesInternal medicinemedicineHumanseducationAgedFatty acids; HDL cholesterol levels; HepG2 cells; Population study; Cardiology and Cardiovascular MedicineCatabolismbusiness.industryCholesterolCholesterol HDLMembrane Proteinsnutritional and metabolic diseasesFatty acidKinetics030104 developmental biologyEndocrinologychemistrybusinessBiomarkersHeparan Sulfate ProteoglycansAtherosclerosis
researchProduct

Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report

2016

Objective— Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant familial hypercholesterolemia. Will PCSK9 inhibition with monoclonal antibodies, in particular alirocumab, be of therapeutic value for patients with autosomal recessive hypercholesterolemia (ARH)? Approach and Results— Primary lymphocytes were obtained from 28 genetically characterized ARH patients and 11 controls. ARH lymphocytes treated with mevastatin were incubated with increasing doses of recombinant PCSK9 with or without saturating concentrations of alirocumab. Cell surface LDL receptor expression measured…

Male0301 basic medicineSettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]receptorsalirocumabFamilial hypercholesterolemia030204 cardiovascular system & hematologyproprotein convertase subtilisin kexin type 90302 clinical medicinetherapeuticsLymphocytesCells CulturedhypercholesterolemiaAnticholesteremic AgentsPCSK9 InhibitorsAntibodies MonoclonalMiddle Aged3. Good healthPhenotypeAutosomal Recessive HypercholesterolemiaKexinDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)LovastatinProprotein Convertase 9Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtySerine Proteinase InhibitorsAdolescentBiologyAntibodies Monoclonal HumanizedLDLYoung Adult03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseLovastatinAdaptor Proteins Signal TransducingAlirocumabPCSK9receptors LDLCholesterol LDLmedicine.diseaseProprotein convertasetherapeutic030104 developmental biologyEndocrinologyCase-Control Studiesalirocumab; hypercholesterolemia; proprotein convertase subtilisin kexin type 9; receptors LDL; therapeutics; Cardiology and Cardiovascular MedicineMutationLDL receptorHydroxymethylglutaryl-CoA Reductase InhibitorsArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hy…

2016

Cholesterol-lowering therapy has been related with several beneficial effects; however, its influence on oxidative stress and endothelial function is not fully elucidated.To investigate the effect of simvastatin and ezetimibe on mitochondrial function and leukocyte-endothelium interactions in polymorphonuclear cells of hyperlipidemic patients.Thirty-nine hyperlipidemic patients were randomly assigned to one of two groups: one received simvastatin (40 mg/day) and the other received ezetimibe (10 mg/day) for 4 weeks, after which both groups were administered combined therapy for an additional 4-week period. Lipid profile, mitochondrial parameters (oxygen consumption, reactive oxygen species (…

Male0301 basic medicineSimvastatinTime FactorsEzetimibe Simvastatin Drug Combination030204 cardiovascular system & hematologyPharmacologymedicine.disease_causechemistry.chemical_compound0302 clinical medicineLeukocytesCells CulturedMembrane Potential Mitochondrialchemistry.chemical_classificationmedicine.diagnostic_testAnticholesteremic AgentsMiddle AgedMitochondriaEndothelial stem cellCholesterolTreatment Outcomemedicine.anatomical_structureFemaleCardiology and Cardiovascular Medicinemedicine.drugEndotheliumAtherosclerosis Ezetimibe Hypercholesterolemia Leukocyte/endothelium interaction Mitochondria Oxidative stress SimvastatinHypercholesterolemiamacromolecular substances03 medical and health sciencesEzetimibeCell AdhesionmedicineHumansAgedReactive oxygen speciesCholesterolbusiness.industryEndothelial CellsEzetimibeCoculture TechniquesOxidative Stress030104 developmental biologychemistrySpainSimvastatinLipid profilebusinessCell Adhesion MoleculesBiomarkersOxidative stress
researchProduct

Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: Data from the European sleep apnea database (ESADA)

2019

Abstract.Gunduz C, Basoglu OK, Hedner J, et al; onbehalf of the European Sleep Apnoea Databasecollaborators (Biruni University; Ege University;Gothenburg University; Sahlgrenska UniversityHospital; University of Palermo; CNR Institute ofBiomedicine and Molecular Immunology; St. AdolfStift; Hospital de Santa Maria; University of Crete;Antoine-Beclere Hospital; G. PapanikolaouHospital; Institute of Tuberculosis and LungDiseases; University Hospital Brno; St. Ann’sUniversity Hospital; Universite ́ Grenoble Alpes)Hyperlipidaemia prevalence and cholesterolcontrol in obstructive sleep apnoea: Data from theEuropean sleep apnea database (ESADA).J InternMed2019;286: 676–688.Background and objective.…

Male0301 basic medicine[SDV]Life Sciences [q-bio]PolysomnographyHyperlipidemiasSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologycomputer.software_genre03 medical and health sciences0302 clinical medicineRisk FactorsDiabetes mellitusPrevalenceInternal MedicineHumansMedicinecholesterol ; hyperlipidaemia ; hypoxia ; obesity ; sleep apnoea.ObesitySleep Apnea ObstructiveDatabasehyperlipidaemiahypoxiabusiness.industryConfoundingcholesterolSleep apneaOdds ratioMiddle Agedmedicine.diseaseObesityrespiratory tract diseases[SDV] Life Sciences [q-bio]EuropeCross-Sectional Studies030104 developmental biologyQuartileCardiovascular DiseasesCohortFemaleHuman medicinebusinesssleep apnoeaBody mass indexcomputer
researchProduct

NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-α and LXR agonists

2020

Reverse cholesterol transport (RCT) and transintestinal cholesterol efflux (TICE) are two important pathways for body cholesterol elimination. We studied these pathways in an animal model of diabetes and obesity (ob/ob) where HDL function is compromised as a result of hyperglycemia, low-grade inflammation and oxidative stress. Co-treatment of ob/ob mice with PPAR-α (fenofibrate) and LXR (T0901317) agonists increased fecal cholesterol by 12-fold; PPAR-α and LXR agonists individually showed 2.6- and 4.0-fold fecal cholesterol excretion, respectively. We investigated the mechanism of synergistic efficacy of PPAR-α and LXR agonists in fecal cholesterol excretion. LXR agonist and the combination…

Male0301 basic medicinemedicine.medical_specialtyHydrocarbons FluorinatedHDLLipoproteinsClinical BiochemistryMice ObeseABCA1NPC1L1Cholesterol 7 alpha-hydroxylaseExcretionFecesMiceob/ob03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFenofibrateInternal medicinemedicineAnimalsPPAR alphaTICEATP Binding Cassette Transporter Subfamily G Member 5Liver X receptorMolecular BiologyLiver X ReceptorsSulfonamidesFenofibratebiologyChemistryCholesterolATP Binding Cassette Transporter Subfamily G Member 8Reverse cholesterol transportMembrane Transport ProteinsDrug SynergismCell BiologyGeneral MedicineCholesterol030104 developmental biologyEndocrinology030220 oncology & carcinogenesisABCA1ABCG5/G8biology.proteinIntestinal cholesterol absorptionlipids (amino acids peptides and proteins)medicine.drugMolecular and Cellular Biochemistry
researchProduct

Cholesterol burden in the liver induces mitochondrial dynamic changes and resistance to apoptosis

2018

Non-alcoholic fatty liver disease (NAFLD) encompasses a broad spectrum of histopathological changes ranging from non-inflammatory intracellular fat deposition to non-alcoholic steatohepatitis (NASH), which may progress into hepatic fibrosis, cirrhosis, or hepatocellular carcinoma. Recent data suggest that impaired hepatic cholesterol homeostasis and its accumulation are relevant to the pathogenesis of NAFLD/NASH. Despite a vital physiological function of cholesterol, mitochondrial dysfunction is an important consequence of dietary-induced hypercholesterolemia and was, subsequently, linked to many pathophysiological conditions. The aim in the current study was to evaluate the morphological a…

Male0301 basic medicinemedicine.medical_specialtyTime FactorsCirrhosisPhysiologyClinical BiochemistryApoptosisMitochondria LiverMitochondrionDiet High-Fatmedicine.disease_causeMitochondrial DynamicsCholesterol Dietary03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineAnimalsCells CulturedCell ProliferationCholesterolbusiness.industryFatty liverCell Biologymedicine.diseaseMice Inbred C57BLDisease Models AnimalOxidative Stress030104 developmental biologymedicine.anatomical_structureEndocrinologyGene Expression RegulationLiverchemistry030220 oncology & carcinogenesisHepatocyteHepatocytesSteatohepatitisTranscriptomeHepatic fibrosisbusinessOxidative stressJournal of Cellular Physiology
researchProduct

Calcium Intake and Nutritional Adequacy in Spanish Children: The ANIVA Study

2017

Calcium is an important nutrient for child development. The main objective of this study was to assess calcium intake and its adequacy with dietary reference intake (DRI) in Spanish children. The ANIVA (Antropometría y Nutrición Infantil de Valencia) study is a descriptive cross-sectional study. During two academic years 2013–2014 and 2014–2015, 1176 schoolchildren aged 6–9 years were selected from 14 primary schools in Valencia (Spain). Three-day food records were used to assess dietary intake, completed by parents/guardian. Anthropometric data (weight and height) were evaluated in all subjects. Nutritional intake was compared to estimated average requirements (EARs) and adequate intake (A…

Male0301 basic medicinemedicine.medical_specialtynutrients intakeNutrition EducationNutritional Statuschemistry.chemical_elementlcsh:TX341-641CalciumRecommended Dietary AllowancesDiet SurveysDiet RecordsReference Daily IntakeArticle03 medical and health sciencesNutrientchildrenEnvironmental healthcalcium ; children ; nutrients intake ; nutritional intakemedicineHumansnutritional intakeFood scienceChildcalcium030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryPublic healthNutritional RequirementsFeeding BehaviorFluorineDietary patternBody HeightDiet RecordsDietCalcium DietaryCholesterolchemistrySpainDietary Reference IntakeFemalechildren; nutritional intake; calcium; nutrients intakeDeficiency Diseasesbusinesslcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct

A Natural Dietary Supplement with a Combination of Nutrients Prevents Neurodegeneration Induced by a High Fat Diet in Mice

2018

Obesity and metabolic disorders can be risk factors for the onset and development of neurodegenerative diseases. The aim of the present study was to investigate the protective effects of a natural dietary supplement (NDS), containing Curcuma longa, silymarin, guggul, chlorogenic acid and inulin, on dysmetabolism and neurodegeneration in the brains of high fat diet (HFD)-fed mice. Decrease in the expression of FACL-4, CerS-1, CerS-4, cholesterol concentration and increase in the insulin receptor expression and insulin signaling activation, were found in brains of NDS-treated HFD brains in comparison with HFD untreated-mice, suggesting that NDS is able to prevent brain lipid accumulation and …

Male0301 basic medicineobesityAntioxidantmedicine.medical_treatmentAnti-Inflammatory AgentsApoptosismedicine.disease_causeSettore BIO/09 - FisiologiaAntioxidantsLipid peroxidationchemistry.chemical_compound0302 clinical medicineinsulin resistanceInsulinnatural antioxidantsNutrition and DieteticsbiologyChemistryneurodegenerationobesity; HFD mice; natural antioxidants; insulin resistance; neurodegenerationBrainfood and beveragesNeurodegenerative Diseaseslipids (amino acids peptides and proteins)Inflammation Mediatorsmedicine.symptomlcsh:Nutrition. Foods and food supplySignal Transductionmedicine.medical_specialtylcsh:TX341-641endocrinology_metabolomicsInflammationDiet High-FatNeuroprotectionArticle03 medical and health sciencesInsulin resistanceInternal medicinemedicineAnimalsHFD miceCholesterolInsulinLipid Metabolismmedicine.diseaseMice Inbred C57BLDisease Models AnimalOxidative StressInsulin receptor030104 developmental biologyEndocrinologyDietary SupplementsNerve Degenerationbiology.proteinLipid Peroxidationnatural antioxidant030217 neurology & neurosurgeryOxidative stressFood ScienceNutrients
researchProduct

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway pr…

2020

Background and aims: Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. Aim of this survey was to evaluate the compliance to ESC/EAS guidelines during the management of ACS patients and the effectiveness of secondary prevention in seven European countries.Methods: By means of an online questionnaire, data on 2775 ACS patients (either acute case or follow-up patients) were collected, including data on lipid profile, medications, follow-up visit planning, screening for familial hypercholesterolemia.Results: Lipid profiles were obtained for 91% of ACS patients in the acute phase…

MaleAcute coronary syndromemedicine.medical_specialtyLow density lipoprotein cholesterolFamilial hypercholesterolemia030204 cardiovascular system & hematologyGuidelinesPatient pathwayLipid-lowering therapy03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicinemedicineGoal achievementHumansIn patientLow-density lipoprotein cholesterol030212 general & internal medicineAgedmedicine.diagnostic_testbusiness.industryAnticholesteremic AgentsStatinsDisease ManagementGeneral MedicineCholesterol LDLLipid-lowering therapiesmedicine.diseaseFemaleAcute coronary syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicineLipid profilebusinessGoals
researchProduct

Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial…

2022

: Background A significant proportion of individuals clinically diagnosed with familial hypercholesterolemia (FH), but without any disease-causing mutation, are likely to have polygenic hypercholesterolemia. We evaluated the distribution of a polygenic risk score, consisting of 12 low-density lipoprotein cholesterol (LDL-C)-raising variants (polygenic LDL-C risk score), in subjects with a clinical diagnosis of FH. Methods and Results Within the Lipid Transport Disorders Italian Genetic Network (LIPIGEN) study, 875 patients who were FH-mutation positive (women, 54.75%; mean age, 42.47±15.00 years) and 644 patients who were FH-mutation negative (women, 54.21%; mean age, 49.73±13.54 years) wer…

MaleAdultMultifactorial InheritanceSettore MED/09 - Medicina Internafamilial hypercholesterolemia; molecular diagnosis; polygenic risk score; Adult; Cholesterol LDL; Female; Humans; Middle Aged; Multifactorial Inheritance; Mutation; Gene Regulatory Networks; Hyperlipoproteinemia Type IIfamilial hypercholesterolemiaCholesterol LDLMiddle AgedLDLHyperlipoproteinemia Type IICholesterolmolecular diagnosispolygenic risk scoreMutationHumansFemaleGene Regulatory Networksmolecular diagnosifamilial hypercholesterolemia; molecular diagnosis; polygenic risk score
researchProduct